Related Experiment Video
Updated: Jun 2, 2026
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia
Ghayas C Issa1, Houry Leblebjian, Aldo M Roccaro
1Medical Oncology, Pharmacy Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Purpose Of Review:
Waldenstrom macroglobulinemia is a distinct low-grade lymphoproliferative disease. There have been recent significant advances in understanding the underlying pathogenesis of this disease, including genetic and epigenetic regulators of tumor progression.
Recent Findings:
Current studies have shown that the tumor microenvironment plays a critical role in cell proliferation, dissemination, and drug resistance.
Summary:
This review provides an update of the advances in the pathogenesis of factors both intrinsic (in the tumor clone) and extrinsic (in the bone marrow microenvironment) that regulate tumor progression in Waldenstrom macroglobulinemia. We next discuss novel agents that have been recently tested in clinical trials based on the advances observed in the pathogenesis of Waldenstrom macroglobulinemia.
